Arcutis projects ZORYVE sales of $455-470 million for 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones
January 12, 2026 8:00 AM ESTContinued strong growth of ZORYVE® (roflumilast) in 2026 with full-year net product sales guidance of $455$470 millionAdvancement of ZORYVE indication-expansion strategy beginning with ongoing Phase 2 proof-of-concept trials in vitiligo and hidradenitis suppurativaInitiation of clinical development program for ARQ-234 in atopic dermatitisTransition to positive cash flows enables investment to both accelerate growth of ZORYVE franchise and advance pipeline
WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, today announced its strategic priorities for 2026.
2025 was a... More
